FRM
PCRX icon

Fox Run Management’s Pacira BioSciences PCRX Stock Holding History

Fox Run Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,092
Closed -$365K – 1153
2025
Q4 		$365K Buy
+14,092
New +$335K 0.06% 630
2023
Q2 		– Sell
-8,963
Closed -$366K – 891
2023
Q1 		$366K Sell
8,963
-7,987
-47% -$318K 0.12% 340
2022
Q4 		$654K Buy
+16,950
New +$825K 0.26% 90
2019
Q3 		– Sell
-9,078
Closed -$395K – 514
2019
Q2 		$395K Buy
9,078
+237
+3% +$10.1K 0.26% 134
2019
Q1 		$336K Buy
+8,841
New +$345K 0.19% 233
2016
Q4 		– Sell
-13,400
Closed -$459K – 629
2016
Q3 		$459K Buy
13,400
+100
+0.8% +$3.92K 0.27% 127
2016
Q2 		$449K Buy
+13,300
New +$654K 0.22% 153

Other funds holding PCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return